4basebio has commercially released a proprietary enzymatic ssDNA platform intended to replace chemical synthesis constraints and enable longer, higher-purity templates for non-viral CRISPR-based gene editing.
The platform supplies high-purity, long-form ssDNA templates with protected ends, designed for stability, reduced immunogenicity and scale-up into clinically viable therapeutics, and the company is a Cambridge-based biotechnology firm focused on synthetic DNA for next-generation therapeutics and vaccines.
"By replacing legacy chemical synthesis with our scalable, cell-free enzymatic approach, we are empowering our partners to design therapies without the traditional constraints of length or sequence complexity," said Amy Walker, CEO of 4basebio.
Amine Bouchareb, Director of Molecular Biology and Gene Editing at 4basebio, will present at the ASGCT Annual Meeting in Boston on 14 May at 9:00 AM EDT, where the company says it will show data that long-form ssDNA constructs enhance homology-directed repair efficiency while maintaining superior cell viability in sensitive primary cell types.
